BT2

SKU: orb1308512

Description

BT2 is a potent and selective Mcl-1 inhibitor (Ki = 59 µM) and a BDK inhibitor (IC50 = 3.19 µM). Its mechanism involves inducing conformational changes in BDK, leading to its dissociation from the BCKDC complex. This compound is a valuable research tool for studying apoptosis and branched-chain amino acid metabolism in cellular and biochemical assays.

Research Area

Cell Biology

Key Properties

• CAS Number: 34576-94-8
• MW: 247.10
• Purity: >98%
• Formula: C₉H₄Cl₂O₂S
• SMILES: OC(=O)C1=C(Cl)C2=C(S1)C=C(Cl)C=C2
• Target: Kinase
• Solubility: Soluble in DMSO (up to at least 20 mg/ml)

Bioactivity

• Target IC50:
  MCL1:59 μM (Ki)|BDK:3.19 μM (IC50)
• In Vivo:
  BT2 treatment reduces the protein levels of BDK in kidneys and heart. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 (20 mg/kg/day; i.p.; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Mcl-1, inhibit, Bcl-2 Family, BDK, BT-2, BT 2, BT2

Compound Identifiers

PubChem CID

739884